

Congenital Heart Defects

A defect in the structure and/or function of the heart due to abnormal development prior to birth

My or may not be detected prior to birth depending on severity of defect

CHD screening – pulse oximetry

Over 35 different abnormalities currently identified

Cyanotic – resulting in "blue" skin due to lack of oxygenated blood in circulation

Acyanotic – "pink" skin due to adequate oxygenation of blood, but poor delivery

CHDs affect nearly 1% of—or about 40,000—births per year in the United States

Most common defect is VSD


About 25% of babies have critical CHDs requiring surgery or other measures


Males > Females

4.2% of all infant deaths occurred due to CHD, and 48% of CHD related deaths occur within 1-year of birth


• Most common birth defect noted worldwide (1.35 million babies per year)

• Risk factors associated with CHDs
• Maternal illness (i.e. pregestational diabetes, phenylketonuria)
• Maternal drug exposure
• Maternal drug e





Patent Ductus Arteriosus • Ductus Arteriosus (bypasses lungs in utero) • Connects pulmonary artery and descending aorta • Remains patent in utero due to low oxygen tension and high levels of circulating PGEs • At birth, oxygen saturation increases and PGE concentration decreases → constriction of the PDA • Functional closure within 96 hrs • Anatomic closure 2 weeks – 3 months





Patent Ductus Arteriosus Ductus may be closed: Pharmacologically Surgical ligation Trans-catheter device (coil) Only CHD where medications CORRECT the lesion Indomethacin Upprofen Acetaminophen


Cyclooxygenase inhibitor Inhibits prostaglandin synthesis Dose: 3 doses given at 12-24hr intervals (dependent on PNA) AE: Renal dysfunction, bleeding, NEC, hyperbilirubinemia No longer considered the "drug of choice"

Cyclooxygenase inhibitor Now has become the "standard of care" May be associated with lower risk of NEC Dose: 10 mg/kg followed by 5 mg/kg at 24hr and 48hr post initial dose AE: renal dysfunction, thrombocytopenia, bleeding

Acetaminophen Blocks the peroxidase segment of prostaglandin synthetase FDA approved for PDA closure Much safer side-effect profile Does not cause peripheral vasoconstriction No effect on platelet aggregation No effect on billirubin displacement Dose: 15 mg/kg every 6 hrs (variable duration)










Pharmacotherapy Post-Operatively - IV may be have mild hypertrophy - Pulmonary vasculature requires time to heal - Often require aggressive diuresis and blood pressure management - Furosemide: loop diuretic (ascending loop of Henle) - 1-2 mg/kg/dose q6h-q24 N/PO - Chlorothiazide: thiazide-like diuretic (distal convoluted tubule) - 5-10 mg/kg/dose q6h-q24 N/V - 10-20 mg/kg/dose q6h-q24 NPO




Atrioventricular Canal (AV Canal)

- Comprised of several abnormalities of structures inside the heart
- Atrial septal defect
- Ventricular septal defect
- Improperly formed mitral/tricuspid valve
- Blood flow to the lungs is <u>higher</u> than normal
- Decreased systemically circulated oxygenated blood

Unbalanced Atrioventricular Canal (AV Canal)


- Left or right dominance occurs (aorta override)
- Often creates hypoplasia of one ventricle
- May require single ventricle physiologic approach
- Often results in pulmonary over circulation and damage to the pulmonary vasculature
- Afterload reduction
- Pulmonary artery band


Drinkwater et al. Semin Thorac Cardiovasc Surg. 1997;9(1):21-5





Narrowing or constriction of the aorta Is outflow obstruction Increased Upressure Decreased peripheral perfusion and oxygenation Pulmonary congestion from high left-sided pressures Patient may remain asymptomatic with mild obstruction Diagnosis typically made after birth


Pharmacotherapy Post-Operatively • LV is acclimated to pumping against coarctation • Often mild-moderate hypertrophy of LV • Autoregulation/remodeling is not immediate • ACEI: inhibits the conversion of angiotensin I to angiotensin II • Captopril – approved for neonates and older (IDI dosing) • Enalapril – approved for reonates and older (BID dosing) • Lisinopril – only approved for ≥ 6 years and older (once daily dosing)











Selective inhibitor of the membrane Na-K pump Increases the force of contraction Decreases automaticity of the AV node Use of digoxin at discharge s/p Norwood procedure has been associated with reduced interstage mortality 10 mcg/kg/day divided BID

Phosphodiesterase-5 inhibitor in smooth muscle of pulmonary vasculature Results in increased GMP concentrations and pulmonary vasculature relaxation Vasculation of the pulmonary bed Bi-directional Glenn creates passive blood flow from the IVC to the PAs High PVR can result in poor pulmonary blood flow and saturations

